Pharmaceutical Solutions: CRO of Choice in Australia and New Zealand

Pharmaceutical Solutions is a New Zealand and Australian based independent CRO, offering personalised clinical research management and regulatory services to the biotechnology and pharmaceutical industry. 

We are proud to promote quality clinical research in our region and proud of our contribution to improving people’s health and wellbeing.

We work closely with you to deliver your project expectations from study design, speed of approval, patient recruitment numbers and quality, to completing the study. We can then work with you to provide Regulatory support to commercialise your product.




We are in the process of building a new Website which should go live shortly.

Pharmaceutical Solutions Business Award

Pharmaceutical Solutions are very excited about being a finalist in the American Chamber of Commerce Success an Innovation Awards 2017.

The awards recognise success in trade and investment between the United States and New Zealand.

Pharmaceutical Solutions Business Award


Fast Approval

This week we celebrated with a client the success of a clinical trial approval through New Zealand Medsafe and Ethics in super quick time

Document Review: 5 days
Medsafe Approval: 22 days
Ethics Approval: 18 days 

Proficient review of documents and efficient processes to address any queries, as well as a good understanding of Medsafe and Ethics timelines are good reasons to work with Pharmaceutical Solutions to conduct clinical research in Australia and New Zealand.

Pharmaceutical Solutions works with New Zealand local authorities and sites to achieve first patient recruitment for global study.

Client Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection

LIMT HDV: Lambda Interferon MonoTherapy in HDV Study

Focused on the development and commercialization of targeted therapies for rare diseases, the client announced today that the first patient was dosed in the Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in HDV) study, a monotherapy trial of pegylated interferon lambda 1a ("Lambda") as a potential treatment for chronic hepatitis D virus (HDV) infection.  LIMT HDV is a 30-patient study designed to evaluate the safety, tolerability and efficacy of two dose levels of Lambda after 48 weeks of treatment.  LIMT HDV is an international study currently enrolling at University of Auckland in New Zealand.